ArticleThe oncologist2025

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

Binliang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.